VolitionRx Announces Acceptance of Compliance Plan by NYSE American

VolitionRx (NYSE AMERICAN: VNRX) announced that on April 22, 2026 the NYSE American accepted its plan of compliance to regain listing standards.

Rhea-AI Summary

VolitionRx (NYSE AMERICAN: VNRX) announced that on April 22, 2026 the NYSE American accepted its plan of compliance to regain listing standards. The company has until August 6, 2027 to restore required stockholders' equity thresholds and will undergo periodic reviews during the Plan Period.

The Acceptance Letter does not affect current listing or the company's SEC reporting obligations.

Positive

• NYSE American accepted Volition's compliance plan on April 22, 2026
• Company granted extension to August 6, 2027 to regain compliance
• Common stock remains listed and tradable during the Plan Period
• Plan submitted before the March 8, 2026 NYSE deadline

Negative

• Company previously found noncompliant with Sections 1003(a)(i)-(iii) on February 6, 2026
• Required stockholders' equity thresholds: $2.0M, $4.0M, $6.0M
• NYSE American may initiate delisting if compliance not regained by August 6, 2027

Argus Apr 23 session

-8.69% close to close Open Argus

Details

News Market Reaction – VNRX

On Apr 23, the day this news came out, VNRX closed 8.69% below the previous close.

Data tracked by StockTitan Argus for the Apr 23 session.

Key Figures

Equity threshold (2-year losses): $2.0 million Equity threshold (3-year losses): $4.0 million Equity threshold (5-year losses): $6.0 million +3 more

Equity threshold (2-year losses)

$2.0 million

NYSE American Section 1003(a)(i) stockholders’ equity requirement

Equity threshold (3-year losses)

$4.0 million

NYSE American Section 1003(a)(ii) stockholders’ equity requirement

Equity threshold (5-year losses)

$6.0 million

NYSE American Section 1003(a)(iii) stockholders’ equity requirement

Market cap exemption level

$50 million

Total market capitalization threshold referenced in Section 1003(a) exemptions

Compliance plan deadline

August 6, 2027

Date by which NYSE American requires VNRX to regain compliance

Plan acceptance date

April 22, 2026

Date NYSE American accepted VNRX’s compliance plan

Historical Context

5 past events · Latest: Apr 20

5 events

1. Apr 20

   Product launch

   24h Move

   -8.7%

   Launch of rNuQ™ webshop expanding Nu.Q® Discover commercialisation.

2. Mar 31

   Earnings update

   24h Move

   -1.0%

   2025 revenue growth, lower operating expenses, reduced net loss and cash burn.

3. Mar 31

   Non-dilutive funding

   24h Move

   +6.3%

   €2.0M non-dilutive Belgian funding to support Nu.Q® portfolio initiatives.

4. Mar 30

   Clinical study data

   24h Move

   -3.4%

   Mayo Clinic study showing elevated Nu.Q® markers in trauma patients with VTE risk.

5. Mar 26

   Conference abstract

   24h Move

   +0.9%

   ELCC abstract on Nu.Q®-based risk stratification in non-small cell lung cancer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nyse american, company guide, continued listing standards, plan of compliance, +1 more

5 terms

nyse american regulatory

"VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" ), a multi-national..."

NYSE American is a stock exchange where companies can list their shares to be bought and sold by investors. It functions like a marketplace, helping businesses raise money and providing investors with opportunities to buy ownership in these companies. Its role is important because it facilitates the trading of smaller or emerging companies, offering investors access to a broader range of investment options.

company guide regulatory

"standards set forth in Section 1003(a)(i) of the NYSE American Company Guide..."

A company guide is a concise profile that explains what a business does, how it makes money, and the key risks and opportunities investors should know. Think of it as a one-page briefing or travel brochure for the firm that helps readers quickly understand the company’s strategy, products, markets and financial outlook so they can compare it to other investments without digging through long reports.

continued listing standards regulatory

"the Company is not in compliance with the NYSE American continued listing standards..."

Ongoing rules a stock exchange requires a listed company to meet to keep its shares trading publicly, such as minimum share price, market value, timely financial reports, and governance practices. Think of it as a membership checklist for a club: falling short can lead to warnings or removal from the exchange, which can sharply reduce liquidity, investor confidence, and a stock’s value. Investors watch these standards to gauge regulatory risk and the stability of their holdings.

plan of compliance regulatory

"the NYSE American LLC (the "NYSE American") accepted the Company's plan of compliance..."

A plan of compliance is a formal roadmap a company creates to fix regulatory or legal problems, listing the steps, timelines and responsible parties needed to meet official rules. Investors care because it indicates how quickly and effectively a company can stop penalties, restore trust and return to normal operations—much like a repair plan for a house that shows when rooms will be fixed and how much it will cost.

delisting proceedings regulatory

"then NYSE American may initiate delisting proceedings."

Delisting proceedings are the formal steps taken to remove a company’s shares from a stock exchange, either because the company chose to leave or failed to meet rules like minimum share price, reporting or solvency requirements. For investors this matters because removal usually cuts trading access and liquidity, can sharply lower the share price, and makes it harder to buy, sell or get transparent information — similar to a product being pulled off supermarket shelves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HENDERSON, Nev., April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026, the NYSE American LLC (the "NYSE American") accepted the Company's plan of compliance for continued listing on the exchange.

As previously reported, on February 6, 2026, the Company received a notice from the NYSE American stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years, and Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders' equity at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years.  The notice also indicated that the Company was not currently eligible for any exemption in Section 1003(a) of the Company Guide (including the exemption provided for companies with total value of market capitalization exceeding $50 million among other things).

The Company was required to submit a plan to the NYSE American by March 8, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards by August 6, 2027. The Company submitted a plan prior to the deadline.

On April 22, 2026, the Company received a notification (the "Acceptance Letter") from the NYSE American that the Company's previously submitted plan to regain compliance with the NYSE American's listing standards (the "Plan") was accepted. In the Acceptance Letter, the NYSE American granted the Company until August 6, 2027 (the "Plan Period") to regain compliance with the continued listing standards.

During the Plan Period, the Company will be subject to periodic review by the NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide during the Plan Period. If the Company does not regain compliance with the NYSE American listing standards by August 6, 2027, or if the Company does not make sufficient progress consistent with the Plan during the Plan Period, then NYSE American may initiate delisting proceedings.

The Acceptance Letter has no immediate impact on the listing of the Company's shares of common stock, which will continue to be listed and traded on the NYSE American during the Plan Period, subject to the Company's compliance with the other listing requirements of the NYSE American. The Acceptance Letter does not affect the Company's ongoing business operations or its reporting requirements with the Securities and Exchange Commission.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

Media Enquiries
Louise Batchelor, Volition mediarelations@volition.com
+44 (0)7557 774620

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding the Company's expectations surrounding regaining compliance with the NYSE American's continued listing standards, and actions of the Company and/or the NYSE American to be taken with respect to matters discussed in the notice and the Acceptance Letter. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Volition believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct.

Forward-looking statements are subject to risks and uncertainties that may cause Volition's actual activities or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties related to the Company's ability to regain compliance with the listing standards set forth in the Company Guide by August 6, 2027, as well as the risks disclosed in other documents Volition files from time to time with the SEC, including Volition's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.

Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

View original content:https://www.prnewswire.com/news-releases/volitionrx-announces-acceptance-of-compliance-plan-by-nyse-american-302751633.html

SOURCE VolitionRx Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did VolitionRx (VNRX) announce about its NYSE American listing on April 22, 2026?

VolitionRx announced the NYSE American accepted its plan of compliance on April 22, 2026. According to Volition, the acceptance grants the company until August 6, 2027 to regain required stockholders' equity and it will be periodically reviewed during the Plan Period.

How long does VolitionRx have to regain NYSE American compliance (VNRX)?

VolitionRx has until August 6, 2027 to regain compliance with listing standards. According to Volition, the NYSE American set the Plan Period during which the company must meet Sections 1003(a)(i)-(iii) or face potential delisting proceedings.

Does the NYSE American Acceptance Letter affect VNRX's current trading status?

No; the Acceptance Letter does not impact the immediate listing or trading of VolitionRx shares. According to Volition, the company's common stock will continue trading on the NYSE American while it works to meet listing requirements.

What equity thresholds must VolitionRx meet to satisfy NYSE American rules (VNRX)?

VolitionRx must meet stockholders' equity thresholds of $2.0M, $4.0M, or $6.0M depending on prior-year losses. According to Volition, these thresholds correspond to Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide.